LASA Stock Overview
Engages in the research, manufacture, and marketing of animal and human healthcare products in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Lasa Supergenerics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹28.81 |
| 52 Week High | ₹41.20 |
| 52 Week Low | ₹19.00 |
| Beta | 0.57 |
| 1 Month Change | 15.29% |
| 3 Month Change | 4.80% |
| 1 Year Change | 3.63% |
| 3 Year Change | -58.87% |
| 5 Year Change | 59.17% |
| Change since IPO | -80.43% |
Recent News & Updates
Recent updates
Little Excitement Around Lasa Supergenerics Limited's (NSE:LASA) Revenues
Dec 10
There's No Escaping Lasa Supergenerics Limited's (NSE:LASA) Muted Revenues
Aug 08We Think Lasa Supergenerics (NSE:LASA) Has A Fair Chunk Of Debt
Jun 05Little Excitement Around Lasa Supergenerics Limited's (NSE:LASA) Revenues As Shares Take 26% Pounding
Mar 13Improved Revenues Required Before Lasa Supergenerics Limited (NSE:LASA) Stock's 25% Jump Looks Justified
Dec 28We Think Lasa Supergenerics (NSE:LASA) Has A Fair Chunk Of Debt
Jul 05Lasa Supergenerics (NSE:LASA) Is Carrying A Fair Bit Of Debt
Mar 28Lasa Supergenerics' (NSE:LASA) Dividend Will Be ₹0.25
Sep 02Would Lasa Supergenerics (NSE:LASA) Be Better Off With Less Debt?
Aug 13A Look At The Fair Value Of Lasa Supergenerics Limited (NSE:LASA)
Jun 21Is Lasa Supergenerics (NSE:LASA) Using Too Much Debt?
Dec 06Shareholder Returns
| LASA | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 6.3% | 0.8% | -4.2% |
| 1Y | 3.6% | 39.7% | 19.1% |
Return vs Industry: LASA underperformed the Indian Pharmaceuticals industry which returned 39.7% over the past year.
Return vs Market: LASA underperformed the Indian Market which returned 19.1% over the past year.
Price Volatility
| LASA volatility | |
|---|---|
| LASA Average Weekly Movement | 5.7% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: LASA has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: LASA's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 77 | Omkar Herlekar | lasalabs.com |
Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. It offers API products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, and halquinol, as well as 2,6-diiodo-4-nitrophenol; and other API products. The company also provides animal feed ingredients, including calcium iodate; and reagents for therapeutic use, such as potassium iodide.
Lasa Supergenerics Limited Fundamentals Summary
| LASA fundamental statistics | |
|---|---|
| Market cap | ₹1.44b |
| Earnings (TTM) | -₹227.18m |
| Revenue (TTM) | ₹1.20b |
1.2x
P/S Ratio-6.4x
P/E RatioIs LASA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LASA income statement (TTM) | |
|---|---|
| Revenue | ₹1.20b |
| Cost of Revenue | ₹939.05m |
| Gross Profit | ₹258.77m |
| Other Expenses | ₹485.95m |
| Earnings | -₹227.18m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.53 |
| Gross Margin | 21.60% |
| Net Profit Margin | -18.97% |
| Debt/Equity Ratio | 22.3% |
How did LASA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 11:04 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Lasa Supergenerics Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|